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POSTOPERATIVE ATRIAL FIBRILLATION 
PROPHYLAXIS AND LUNG RESECTION 
– OUR EXPERIENCE WITH 608 CONSECUTIVE PATIENTS
Vjekoslav Karadža, Dinko Stančić-Rokotov, Jasna Špiček Macan, Nevenka Hodoba, 
Nevenka Kolarić and Sanja Sakan
Jordanovac Department of Th oracic Surgery, Zagreb University Hospital Center, Zagreb, Croatia
SUMMARY – Postoperative atrial fi brillation is a common complication after lung resection. It 
is burdened by increased mortality and morbidity, prolonged hospitalization, and higher resource 
 utilization in thoracic surgery patients. Th erefore, some kind of pharmacological prophylaxis is recom-
mended. In our patients, diltiazem, a calcium antagonist, is administered. We collected data on all 608 
patients having undergone lung resection (no less than lobectomy) between November 2012 and May 
2015. Th is period included patients having received diltiazem during their postoperative stay in our 
Intensive Care Unit and surgical ward, and those that did not receive it. Patients having had atrial 
 fi brillation before the surgery and patients with cardiac pacemaker were excluded from the trial.  Other 
patients were divided into three groups: patients with some kind of antiarrhythmic therapy before and 
continued after the surgery; patients with diltiazem prophylaxis; and patients without any anti-
arrhythmic prophylaxis. Th e data collected were statistically analyzed. We found no statistically 
 signifi cant diff erence in the incidence of postoperative atrial fi brillation among the groups (p<0.05).
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Introduction
According to the literature, postoperative atrial fi -
brillation (POAF) (or equivalent supraventricular ar-
rhythmia) is a common complication after pulmonary 
and esophageal surgery, with the incidence between 
12% and 44%1,2 . Some risk factors have been identi-
fi ed, correlation with perioperative mortality and mor-
bidity has been demonstrated, and prophylactic and 
therapeutic guidelines have been developed1,2. POAF 
is associated with hemodynamic instability, heart fail-
ure, thromboembolic events, higher resource utiliza-
tion and, possibly, increased mortality1. Th e precise 
mechanism of POAF development is not well under-
stood1. Th e risk factors include history of smoking, 
obesity, advancing age, atrial dilatation, myocardial 
ischemia, volume overload, history of heart failure, in-
creased adrenergic and vagal tone, and surgical proce-
dures associated with local or systemic infl ammation1,2. 
Th e extent of pulmonary resection is of importance as 
a risk factor, with the highest rates of incidence noted 
after pneumonectomies, extrapleural pneumonecto-
mies and lung transplantations2. Lobectomies and 
pneumonectomies are recognized as high risk proce-
dures with POAF incidence above 15%1. Among 
drugs recommended for the prophylaxis of POAF and 
equivalent postoperative arrhythmias is diltiazem, a 
calcium antagonist2,3. It has few side eff ects and, with 
respect to known contraindications, it is well tolerated, 
especially in patients with chronic obstructive pulmo-
nary disease (COPD)2.
Patients and Methods
Th is observational study was performed at Jordan-
ovac Department of Th oracic Surgery, Zagreb Univer-
sity Hospital Centre, Zagreb, Croatia. Data from med-
V. Karadža et al. POAF prophylaxis and lung resection
Acta Clin Croat, Vol. 56, No. 1, 2017 65
ical records of all patients having undergone pulmo-
nary resection procedures with a high risk of POAF1 
(lobectomies, bilobectomies and pneumonectomies) 
between November 2012 and May 2015 were includ-
ed in the study. It was the time of introducing diltia-
zem for atrial fi brillation (AF) prophylaxis in our pa-
tients, thus including patient data before and during 
the introduction of diltiazem prophylaxis. Th e follow-
ing data were collected: patient age, sex, the American 
Society of Anesthesiologists Physical Status (ASA 
status), comorbidity (coronary disease, arterial hyper-
tension, other cardiac diseases and arrhythmias, preop-
erative chemotherapy, preoperative irradiation, hypo-/
hyperthyroidism, diabetes mellitus, renal insuffi  ciency, 
alcoholic cirrhosis, concomitant malignancy), relevant 
preoperative drug therapy, lung resection type (extent, 
intrapericardial, extrapleural), use/no use of thoracic 
epidural analgesia (TEA), use/no use of POAF pro-
phylaxis (and if, what kind), presence/absence of post-
operative fi brillation and equivalent arrhythmia, and 
the highest ventricular response recorded during 
POAF. Th e choice of risk factors and collected data 
was determined by the data available from medical re-
cords. All patients had spent at least one night, most of 
them two or more nights, in the Intensive Care Unit 
(ICU) before they were admitted to thoracic surgery 
ward. Patients were divided into three groups: group A 
included patients with no POAF prophylaxis; group B 
included patients with diltiazem prophylaxis; and 
group C included patients with preoperative antiar-
rhythmic therapy (mostly beta-blockers, a few propafe-
none or amiodarone) that was continued postopera-
tively. Diltiazem was included in therapy, if there were 
no contraindications, on the day of surgery or the fi rst 
postoperative day (according to clinical circumstances) 
and continued after transfer from ICU to surgical 
ward. A patient was included in group B if the 
24-hour diltiazem dose was at least 60 mg (usually it 
was between 60 mg and 240 mg per os divided in 2-4 
doses). All patients were treated equally according to 
the ICU and surgical ward perioperative treatment 
protocol. All patients gave their informed consent 
for participation in the study. Statistical analysis and 
data analysis were done by the licensed STATISTI-
CA 6.1 StatSoft Inc. 1983-2003 (serial number 
AGA304B211928E61) software. Th e sample was pre-
sented by descriptive statistics and frequency tables. 
Correlation between the highest recorded ventricular 
frequency of AF and other parameters was tested by 
the analysis of variance (ANOVA) and t-test for inde-
pendent samples. Correlation between the incidence 
of AF and other parameters was presented in contin-
gency tables and tested by χ2-test. Results of statistical 
analysis were presented graphically and numerically 
(in tables). Statistical testing was performed at the 
level of signifi cance of 95% (α=0.05).
Table 1. Extent of lung resection
Frequency table











PD = right pneumonectomy; PS = left pneumonectomy; BID = 
right inferior bilobectomy; BSD = right superior bilobectomy; LID 
= right inferior lobectomy; LSS = left superior lobectomy; LIS = 
left inferior lobectomy; LSD = right superior lobectomy; LMD = 
right middle lobe resection






Table 3. Prophylaxis groups
Frequency table 
Atrial fi brillation prophylaxis n %
Diltiazem 221 37.5
Preoperative antiarrhythmic therapy 132 22.4
None 236 40.1
Total 589 100.0
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Table 4. Postoperative atrial fi brillation prophylaxis and incidence









Yes 27 16 34 77
% 35.06% 20.78% 44.16%
No 194 116 202 512
% 37.89% 22.66% 39.45%
Total 221 132 236 589
AF = atrial fi brillation
Table 5. Statistics: POAF and POAF prophylaxis (AF)
Statistics: AF(2) x AF prophylaxis(3) 
χ2-test df p
Pearson χ2-test 0.617 2 0.734
POAF = postoperative atrial fi brillation; AF = atrial fi brillation
POAF = postoperative atrial fi brillation; AF = atrial fi brillation
Fig. 1. POAF prophylaxis and incidence.
Results
Th ere were 608 patients undergoing lung resection 
greater or equal to lobectomy during the period of 31 
months. As 15 patients with chronic AF and four pa-
tients with some kind of pacemaker were excluded, 
there remained 589 patients with lung resection for 
further analysis (Table 1). Seventy-seven of these 589 
patients developed POAF (13.1%) (Table 2). Th ere 
were 82 pneumonectomies with 19 (23.17%) cases of 
POAF. According to their AF prophylaxis, these 589 
patients were divided into 3 groups: group A, 236 pa-
tients without prophylaxis; group B, 221 patients with 
diltiazem prophylaxis; and group C, 132 patients 
with continued preoperative antiarrhythmic therapy 
(Table 3). POAF was recorded in 34 (14.41%) group 
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A patients, 27 (12.22%) group B patients and 16 
(12.12%) group C patients. Th e highest ventricular 
 response in AF was recorded in each patient, with 
 median 160 (range 91-230) in group A, 150 (range 












Total 77 149.6234 22.79430 2.597651 144.4497 154.7970
Diltiazem 27 148.1481 20.48208 3.941778 140.0457 156.2506
Preoperative antiarrhythmic 
therapy
16 146.2500 14.24313 3.560782 138.6604 153.8396
None 34 152.3824 27.54502 4.723932 142.7714 161.9933
POAF = postoperative atrial fi brillation; AF = atrial fi brillation; SD = standard deviation; SE = standard error
Fig. 2. Testing of the highest ventricular frequency observed and POAF prophylaxis.










Table 8. Age groups and POAF (AF)








≤55 9 101 110
 % 8.18% 91.82%
56-64 27 221 248
 % 10.89% 89.11%
65-74 30 160 190
 % 15.79% 84.21%
≥75 11 30 41
 % 26.83% 73.17%
Total 77 512 589
POAF = postoperative atrial fi brillation; AF = atrial fi brillation
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Table 11. Sex and POAF incidence (AF)







Male 60 329 389
 % 15.42% 84.58%
Female 17 183 200
 % 8.50% 91.50%
Total 77 512 589
POAF = postoperative atrial fi brillation; AF = atrial fi brillation
Table 9. Statistics: age groups and POAF (AF)
Statistics: age group(4) x AF(2)
χ2-test df p
Pearson χ2-test 11.41967 3 0.00966
POAF = postoperative atrial fi brillation; AF = atrial fi brillation






Table 12. Statistics: sex and POAF (AF)
Statistics: sex(2) x AF(2) 
χ2-test df p
Pearson χ2-test 5.573 1 0.018
POAF = postoperative atrial fi brillation; AF = atrial fi brillation
Table 13. Lung resection extent and POAF (AF) 
2-way summary table: frequencies observed 
Lung 
resection
AF yes AF no Total
PD 3 23 26
 % 11.54% 88.46%
PS 16 40 56
 % 28.57% 71.43%
BID 2 25 27
 % 7.41% 92.59%
BSD 3 13 16
 % 18.75% 81.25%
LID 8 69 77
 % 10.39% 89.61%
LSS 16 105 121
 % 13.22% 86.78%
LIS 9 73 82
 % 10.98% 89.02%
LSD 16 133 149
 % 10.74% 89.26%
LMD 4 31 35
 % 11.43% 88.57%
Total 77 512 589
POAF = postoperative atrial fi brillation; AF = atrial fi brillation; PD 
= right pneumonectomy; PS = left pneumonectomy; BID = right 
inferior bilobectomy; BSD = right superior bilobectomy; LID = 
right inferior lobectomy; LSS = left superior lobectomy; LIS = left 
inferior lobectomy; LSD = right superior lobectomy; LMD = right 
middle lobe resection
Table 14. Statistics: lung resection extent and POAF (AF)
Statistics: lung resection(9) x AF(2) 
χ2-test df p
Pearson χ2-test 14.71278 8 0.06499
POAF = postoperative atrial fi brillation; AF = atrial fi brillation
110-210) in group B and 148 (range 125-170) in 
group C. Th e χ2-test showed no statistically signifi cant 
diff erence in the incidence of AF among patients with 
diff erent AF prophylaxis (p>0.05) (Tables 4 and 5, Fig. 
1). Analysis of variance (ANOVA) yielded no statisti-
cally signifi cant diff erence among patients with diff er-
ent AF prophylaxis with respect to the highest ven-
tricular frequency. Patients without prophylactic anti-
arrhythmic drugs had higher ventricular frequency 
during AF but this diff erence was not statistically sig-
nifi cant (p>0.05) (Table 6, Fig. 2). Analysis of correla-
tion of particular risk factors with POAF yielded sta-
tistically signifi cant correlation (p<0,05) for age (Ta-
bles 7, 8 and 9), sex (Tables 10, 11 and 12), pneumo-
nectomy versus other resections (Tables 13, 14, 15 and 
16), generalized atherosclerotic disease (in our study, it 
was defi ned as comorbidity including history of myo-
cardial infarction or cerebrovascular insult, diagnosis 
of coronary disease and peripheral vascular disease) 
(Tables 17, 18 and 19), and ASA status (Tables 20, 21 
and 22). Considering other states and comorbidities, 
V. Karadža et al. POAF prophylaxis and lung resection
Acta Clin Croat, Vol. 56, No. 1, 2017 69
Table 15. Pneumonectomies and POAF (AF)






PD + PS 19 63 82
 % 23.17% 76.83%
Other 58 449 507
 % 11.44% 88.56%
Total 77 512 589
POAF = postoperative atrial fi brillation; AF = atrial fi brillation; 
PD = right pneumonectomy; PS = left pneumonectomy
Table 16. Statistics: pneumonectomies and POAF
Statistics: PD + PS(2) x AF(2) 
χ2-test df p
Pearson χ2-test 8.547484 1 0.00346
POAF = postoperative atrial fi brillation; AF = atrial fi brillation; 
PD = right pneumonectomy; PS = left pneumonectomy






Table 18. Generalized atherosclerotic disease and POAF







Yes 16 62 78
Row % 20.51% 79.49%
No 61 450 511
Row % 11.94% 88.06%
Total 77 512 589
GAD = generalized atherosclerotic disease; POAF = postoperative 
atrial fi brillation; AF = atrial fi brillation
Table 19. Statistics: generalized atherosclerotic disease 
and POAF
Statistics: GAD(2) x AF(2) 
χ2-test df p
Pearson χ2-test 4.379084 1 0.03639
GAD = generalized atherosclerotic disease; POAF = postoperative 
atrial fi brillation; AF = atrial fi brillation
Table 20. ASA status
Frequency table
ASA status n %
<ASA III 237 40.2
≥ASA III 352 59.8
Total 589 100.0
ASA status = American Society of Anesthesiologists Physical  Status
Table 21. ASA status and POAF incidence (FA)
2-way summary table: frequencies observed; marked 
cells had counts >10
AF AF Row
<ASA III 18 219 237
Row % 7.59% 92.41%
≥ASA III 59 293 352
Row % 16.76% 83.24%
Total 77 512 589
ASA status = American Society of Anesthesiologists Physical Sta-
tus; POAF = postoperative atrial fi brillation; AF = atrial fi brillation
Table 22. Statistics: ASA status and POAF incidence (FA)
Statistics: ASA status(2) x AF(2) 
χ2-test df p
Pearson χ2-test 10.47239 1 0.00121
ASA status = American Society of Anesthesiologists Physical Sta-
tus; POAF = postoperative atrial fi brillation; AF = atrial fi brillation
statistical analysis did not show statistical signifi cance, 
e.g., thoracic epidural analgesia (Tables 23, 24 and 25), 
arterial hypertension (Tables 26, 27 and 28) and prior 
chemotherapy (Tables 29, 30 and 31), or the entities 
were too rare in our patients to be included in the anal-
ysis, e.g., diabetes mellitus, renal insuffi  ciency and Teo-
lin therapy.
Discussion
Th e search for the ideal antiarrhythmic for POAF 
prophylaxis is far from fi nished. Avoidance of β block-
ade withdrawal in patients on chronic therapy with 
these medications is the simple and most eff ective pre-
ventive measure1,2,4. As with AF therapy, there is no 
ideal drug or method for POAF prevention in other 
patients. Magnesium supplementation is usually rec-
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Table 24. TEA and POAF (FA)







Yes 36 250 286
 % 12.59% 87.41%
No 41 262 303
 % 13.53% 86.47%
Total 77 512 589
TEA = thoracic epidural analgesia; POAF = postoperative atrial 
fi brillation; AF = atrial fi brillation
Table 25. Statistics: TEA and POAF (FA)
Statistics: TEA(2) x FA(2) 
χ2-test df p
Pearson χ2-test 0.1153593 1 0.73412
TEA = thoracic epidural analgesia; POAF = postoperative atrial 
fi brillation; AF = atrial fi brillation
Table 26. Arterial hypertension
Frequency table 




Table 27. Arterial hypertension and POAF incidence







Yes 40 232 272
 % 14.71% 85.29%
No 37 280 317
 % 11.67% 88.33%
Total 77 512 589
AH = arterial hypertension; POAF = postoperative atrial fi brilla-
tion; AF = atrial fi brillation
Table 28. Statistics: arterial hypertension and POAF
Statistics: AH(2) x AF(2)
χ2-test df p
Pearson χ2-test 1.185774 1 0.27619
AH = arterial hypertension; POAF = postoperative atrial fi brilla-
tion; AF = atrial fi brillation
ommended1 and regularly administered in our patients. 
Some of the established antiarrhythmics such as amio-
darone have questionable safety, especially in patients 
with pneumonectomy and COPD1,2,5. Diltiazem has 
been established as a prophylactic antiarrhythmic drug 
with moderate success1,2. It is recommended early 
postoperatively, especially in COPD patients, and is 
usually well tolerated3. Diltiazem is a nondihydropyri-
dine calcium channel antagonist (class IV Vaughan 
Williams agent)6. As AF prophylaxis, we administer it 
in oral form. In our study, we found no statistically sig-
nifi cant diff erence between patient groups with and 
without diltiazem prophylaxis, suggesting that in our 
patients, POAF occurred as a complication of lung re-
section comparably often with and without diltiazem 
prophylaxis. So, we could not confi rm the report by 
Amar et al. on diltiazem therapy and its signifi cant 
POAF rate reduction3. Our speculation that patients 
with diltiazem prophylaxis generally have somewhat 
slower ventricular response during POAF (median 
150; without any prophylaxis, median 160), which 
could have some protective properties per se, was not 
confi rmed by statistical analysis. Maybe the most 
problematic part of the study was the uneven dosage of 
diltiazem postoperatively, especially on day 0; also, un-
derdosing was probably quite common due to hemo-
dynamic instability of patients at that time. However, 
Hiran et al.2 in their guidelines suggest that diltiazem 
prophylaxis per os be initiated in recovery room at a 
dose of 30-60 mg every 6 hours, depending on the pa-
tient related factors and with “hold parameters”, and 
we did so accordingly. Th ere is also the issue of the oral 
route of taking the drug and its gastrointestinal re-
sorption in the early postoperative course. In our study, 
the incidence of POAF was 13.1%, which is consistent 
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Table 30. Prior chemotherapy and POAF incidence
2-way summary table: frequencies observed; marked 







Yes 14 113 127
% 11.02% 88.98%
No 63 399 462
 % 13.64% 86.36%
Total 77 512 589
POAF = postoperative atrial fi brillation; AF = atrial fi brillation; 
CHT = chemotherapy
Table 31. Statistics: prior chemotherapy and POAF 
incidence
Statistics: CHT(2) x AF(2) 
χ2-test df p
Pearson χ2-test 0.5984023 1 0.43919
POAF = postoperative atrial fi brillation; CHT = chemotherapy
with literature data2, where it is reported to be 12%- 
44%. If we exclude pneumonectomies, then our POAF 
incidence was 11.4%. As most of our patients were 
transferred from the ICU on postoperative day 2, we 
can speculate that there were much more unnoticed 
and asymptomatic POAF episodes on surgical ward. 
We confi rmed literature reports on patient age, sex, 
pneumonectomy (especially intrapericardial and extra-
pleural extensions) and generalized atherosclerotic 
disease (i.e. coronary disease) as risk factors1,2 (statisti-
cally signifi cant results). Some other risk factors could 
not be confi rmed due to the relatively low number of 
aff ected patients in our sample (hyperthyroidism, car-
diac diseases other than coronary disease, arrhythmias, 
diabetes mellitus, etc.)1,2. We believe that there were 
more patients with these risk factors, but it was not 
recorded in their medical documentation. It should be 
noted that we found a statistically signifi cant correla-
tion between ASA status and POAF, but not between 
epidural analgesia/anesthesia and POAF. ASA status, 
as stated in the literature, correlates with perioperative 
mortality “even better than other classifi cations of 
mortality and morbidity”7,8. TEA is considered to ex-
ert some protective eff ect against POAF9. Arterial hy-
pertension was not confi rmed as a risk factor for 
POAF, in contrast to the 2014 American Heart As-
sociation Atrial Fibrillation Guidelines and relevant 
literature1,2,4. Preoperative chemotherapy, indicated as a 
risk factor for postoperative cardiovascular events10, 
does not seem to increase the risk of POAF. To estab-
lish more defi nitive conclusions, additional study in a 
bigger sample and including more and better defi ned 
risk factors is needed.
References
 1. Frendel G, Sodickson AC, Chung MK, et al. 2014 AATS 
guidelines for the prevention and management of perioperative 
atrial fi brillation and fl utter for thoracic surgery procedures. J 
Th orac Cardiovasc Surg. 2014;148:153-93, http://dx.doi.org/
10.1016/j.jtcvs.2014.06.036
 2. Hiran CF, Jaklitsch MT, Walsh GL, et al. Th e Society of Th o-
racic Surgeons practice guideline on the prophylaxis and man-
agement of atrial fi brillation associated with general thora-
cic surgery: executive summary. Ann Th orac Surg. 2011;92:
1144-52. http://dx.doi.org/10.1016/j.athoracsur.2011.06.104
 3. Amar D, Roistacher N, Rusch VW, et al. Eff ects of diltiazem 
prophylaxis on the incidence and clinical outcome of atrial 
 arrhythmias after thoracic surgery. J Th orac Cardiovasc Surg. 
2000;120:790-8 http://dx.doi.org/10.1067/mtc.2000.109538
 4. January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS 
Guideline for the Management of Patients with Atrial Fibril-
lation: Executive Summary. A Report of the American College 
of Cardiology/American Heart Association Task Force on 
Practice Guidelines and the Heart Rhythm Society. J Am Coll 
Cardiol. 2014;64(21):2246-80, https://dx.doi.org/10.1161/
CIR.0000000000000040
 5. Van Mieghem W, Coolen L, Malysse I, Lacquet LM, Deneff e 
GJ, Demedts MG. Amiodarone and the development of 
ARDS after lung surgery. Chest. 1994;105:1642-5, http://dx.
doi.org/10.1378/chest.105.6.1642
 6. Echizen H, Eichelbaum M. Clinical pharmacokinetics of vera-
pamil, nifedipine and diltiazem. Clin Pharmacokinet. 1986;
11:425-49, https://dx.doi.org/10.2165/00003088-198611060-
-00002
 7. Sidi A, Lobato EB, Cohen JA. Th e American Society of Anes-
thesiologists’ Physical Status: category V revisited. J Clin Anes-
V. Karadža et al. POAF prophylaxis and lung resection
72 Acta Clin Croat, Vol. 56, No. 1, 2017
th. 2000;12(4):328-34, http://dx.doi.org/10.1016/S0952-8180
(00)00168-9
 8. Wolters U, Wolf T, Stutzer H, Schroder T. ASA classifi cation 
and perioperative variables as predictors of postoperative out-
come. Br J Anesth. 1996;77:217-22, https://doi.org/10.1093/
bja/77.2.217
 9. Hanna MN, Murphy JD, Kumar K, Wu CI. Regional tech-
niques and outcome: what is the evidence? Curr Opin Anaes-
thesiol. 2009;22(5):672-7, https://dx.doi.org/ 10.1097/ACO.
0b013e32832f330a
10. Ferguson MK, Saha-Chaudhuri P, Mitchel JD, Varela G, 
Brunelli A. Prediction of major cardiovascular events after lung 




PROFILAKSA POSLIJEOPERACIJSKE ATRIJSKE FIBRILACIJE I RESEKCIJA PLUĆA 
– NAŠA ISKUSTVA SA 608 UZASTOPNIH BOLESNIKA
V. Karadža, D. Stančić-Rokotov, J. Špiček Macan, N. Hodoba, N. Kolarić i S. Sakan
Poslijeoperacijska atrijska fi brilacija je česta komplikacija resekcije pluća. Ona dovodi do povišenog pobola i smrtnosti, 
produljenog bolničkog liječenja i povećane potrošnje sredstava u torakokirurških bolesnika. U skladu s tim, savjetuje se neki 
oblik farmakološke profi lakse. U naših bolesnika odabrani lijek je kalcijev antagonist diltiazem. Skupili smo podatke o svih 
608 bolesnika podvrgnutih resekciji pluća (ne manjoj od lobektomije) u razdoblju između studenog 2012. i svibnja 2015. Ovo 
razdoblje uključuje bolesnike koji su primali diltiazem tijekom njihova poslijeoperacijskog boravka u Jedinici intenzivnog 
liječenja i na kirurškom odjelu te bolesnike koji ga nisu primali. Bolesnici s atrijskom fi brilacijom prije operacije i bolesnici s 
elektrostimulatorom srca isključeni su iz obrade. Ostali bolesnici podijeljeni su u tri skupine: skupinu liječenu nekim anti-
aritmikom prije operacije koji su nastavili svoju terapiju i nakon operativnog zahvata, skupinu na profi laksi diltiazemom i 
skupinu bez profi lakse. Skupljeni podaci su statistički analizirani. Nismo našli statistički značajnu razliku između skupina u 
incidenciji poslijeoperacijske atrijske fi brilacije (p<0,05).
Ključne riječi: Diltiazem; Atrijska fi brilacija; Torakalna kirurgija
